Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-time-in-human study of CMX521 for treatment and/or prevention of norovirus infection

Next Previous
X
Search
Trial Profile

First-time-in-human study of CMX521 for treatment and/or prevention of norovirus infection

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CMX-521 (Primary)
  • Indications Norovirus infections
  • Focus Adverse reactions; First in man; Pharmacokinetics

    • Most Recent Events

    • 08 Nov 2018 According to a Chimerix media release, results for this trial were presented in a financial report
    • 08 Nov 2018 According to a Chimerix media release, data from this trial was presented data on CMX521 at the European Society for Clinical Virology in Athens, Greece
    • 08 Aug 2018 According to a Chimerix media release, the first presentation of clinical data on CMX521 will be in September at the European Society for Clinical Virology in Athens, Greece.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top